Wenqing Wei. Clinical predictive values of biomarker levels in non-small cell lung cancer. Oncol Transl Med, 2017, 3: 245-248.
Clinical predictive values of biomarker levels in non-small cell lung cancer
Received:July 18, 2017  Revised:January 21, 2018
View Full Text  View/Add Comment  Download reader
KeyWord:non-small cell lung cancer; PD-1; IL-17; IL-21
Author NameAffiliationE-mail
Wenqing Wei Army General Hospital, Beijing, 100700, China wqwei2000@qq.com 
Hits: 7608
Download times: 8108
Abstract:
      Objective To evaluate the predictive value of serum levels of PD-1, IL-17, and IL-21 in patients with nonsmall cell lung cancer. Methods Serum levels of PD-1, IL-17, and IL-21 were analyzed by ELISA in 45 patients with non-small cell lung cancer (NSCLC) and 30 healthy individuals. Results Serum PD-1, IL-17, and IL-21 levels were significantly different between preoperative patients with NSCLC and the control group (P < 0.01), while there was no significant differences between the postoperative patients and the control group (P > 0.05). Comparison of serum PD-1, IL-17, and IL-21 levels of patients with NSCLC before and after the operation revealed a decrease in PD-1 and IL-17 levels and an increase in IL-21 levels. The serum levels of PD-1 and IL-17 were higher in patients with advanced staged disease than in those with early stage cancer (P < 0.05), while IL-21 levels were lower at the advanced stages (P < 0.05). Conclusion In patients with NSCLC, serum levels of PD-1, IL-17, and IL-21 changed considering the surgical operation and the course of the disease. Screening these biomarker levels might provide a helpful index for treatment and prognosis.
Close